Detail akcie Repare Therap Rg online

Business Summary: Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Repare Therapeutics Inc revenues decreased from $52.4M to $0K. Net loss totaled $30M vs. income of $13.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Interest income decrease of 48% to $1.5M (income), General and administrative - Balancing increase of 8% to $6M (expense).